<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117278">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576276</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000358</org_study_id>
    <nct_id>NCT01576276</nct_id>
  </id_info>
  <brief_title>A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects</brief_title>
  <official_title>A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy right-handed volunteers aged 21 to 50 needed for a research study of the effects of
      morphine and ketorolac on brain activity in response to pain stimuli as measured by
      functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET). Study
      will be conducted on six separate days not requiring an overnight stay in the hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET and fMRI signal changes</measure>
    <time_frame>one day</time_frame>
    <description>Obtain information about brain activity (including BOLD signal and opioid binding potential) using an integrated PET &amp; fMRI system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain ratings</measure>
    <time_frame>5 sessions involving pain ratings</time_frame>
    <description>Characterize analgesic response to morphine and ketorolac using pain ratings</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Morphine condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI-only</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Integrated MR-PET scan</intervention_name>
    <description>Integrated MR-PET scan using [11C]diprenorphine</description>
    <arm_group_label>Morphine condition</arm_group_label>
    <arm_group_label>Ketorolac condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>3 administrations of ketorolac over course of study</description>
    <arm_group_label>Ketorolac condition</arm_group_label>
    <arm_group_label>Pilot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>3 administrations of morphine over course of study</description>
    <arm_group_label>Morphine condition</arm_group_label>
    <arm_group_label>Pilot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female adults, aged 21-50

          2. No contraindications to fMRI scanning

          3. Within 15% of normal BMI

          4. Right handed (dominant hand is right hand)

          5. Have taken an opioid drug at least once in the past (for example, after a surgery)

        Exclusion Criteria:

          1. Current or past history of major medical, neurological, or psychiatric illness

          2. Women who are pregnant or breast feeding, have gone through menopause, or have
             irregular menstrual cycles (length of cycle must be within 26 to 32 days)

          3. Contraindications to morphine administration:

               -  i) Hypersensitivity to morphine or other phenanthrene-derivative opioid agonists
                  (codeine, oxycodone, etc.), morphine salts, or any component of the product

               -  ii) Concomitant use of other CNS depressants including antihistamines or alcohol

               -  iii) History of drug or alcohol abuse

               -  iv) History of head trauma

               -  v) History of liver problems

               -  vi) Pre-existing respiratory conditions (ex. COPD, asthma)

               -  vii) Current use of any drugs that interact with morphine

          4. Contraindications to ketorolac administration

               -  i) Allergic-type reaction, or urticaria in response to exposure to aspirin or
                  other NSAIDS

               -  ii) Concomitant aspirin or NSAID use

               -  iii) Hypersensitivity previously demonstrated to ketorolac tromethamine or to
                  any product component

               -  iv) Peptic ulcer disease (active or history), or other gastrointestinal problems

               -  vi) Current use of any drugs that interact with ketorolac (ex. heparin/warfarin)

               -  vii) History of bleeding disorder

               -  viii) Low body weight, under 50 kg

          5. Contraindications to fMRI scanning (including cardiac pacemaker, metal implants,
             claustrophobia, pregnancy)

          6. Contraindications to either of the emergency medications (Ondansetron or Narcan)

          7. History of head trauma

          8. High blood pressure (&gt;140 systolic, &gt;90 diastolic)

          9. History of impaired urinary elimination

         10. Major kidney problems, bleeding problems, severe dehydration, or recovering from a
             recent surgery (within past year).

         11. Instability of responses to experimental pain (see Study Procedures Section)

         12. History of asthma

         13. History of diabetes

         14. Liver Function Test results greater than 2.5 times the upper limit of normal (ULN) at
             Screening

         15. History of smoking (past or current)

         16. Use of psychotropic drugs, hormone treatments (including hormonal birth control)
             within 1 year

         17. Non-fluent speaker of English

         18. Positive urine drug screen (i.e. positive on any of the 10 measures tested, including
             cocaine, marijuana, opiates, amphetamines, methamphetamines, phencyclidine,
             barbiturates, benzodiazepines, methadone, and tricyclic antidepressants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Sun, BS</last_name>
      <phone>617-726-5004</phone>
      <email>ssun6@partners.org</email>
    </contact>
    <investigator>
      <last_name>Jian Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>February 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jian Kong</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
